Personalized Phage Therapy for Recurrent Urinary Tract Infections: Inside the P-PEAKS UTI Clinical Trial

-

Recurrent urinary tract infections (rUTIs) remain one of the most prevalent bacterial diseases worldwide, affecting millions of women each year and placing a substantial burden on healthcare systems. These infections are not only painful and disruptive to daily life, but they also represent a growing clinical challenge in the context of escalating antimicrobial resistance. In many patients, particularly those experiencing recurrent episodes, antibiotics gradually lose their effectiveness. Repeated exposure promotes the emergence of resistant bacterial strains, alters the composition of the microbiota, and often fails to prevent relapse. As a result, patients frequently enter a cycle of infection, treatment, temporary relief, and recurrence that can persist for years.

© The Phage Therapy

A central factor underlying this persistence is the ability of uropathogenic Escherichia coli (UPEC) to form biofilms within the urinary tract. These biofilms are structured bacterial communities embedded in a self-produced extracellular matrix composed of polysaccharides, proteins, and DNA. This matrix acts as a physical and biochemical barrier, limiting antibiotic penetration and protecting bacteria from host immune defenses. Within biofilms, bacteria can enter a dormant or slow-growing state, further reducing antibiotic susceptibility. These characteristics make biofilm-associated infections particularly difficult to eradicate and are a major reason why conventional therapies often fail in recurrent cases.

Recognizing the urgent need for alternative therapeutic strategies, the European Union has invested €15.6 million in the P-PEAKS UTI project (Personalized-Phage Against E. coli with IV Antibiotic to Knockout Stable Biofilms in Urinary Tract Infections). This ambitious initiative is one of three flagship projects funded under the Horizon Europe program dedicated to evaluating bacteriophage therapy for antibiotic-resistant infections. The project is coordinated by Unity Health Toronto, a leading Canadian academic health network known for its expertise in infectious diseases and clinical research. According to detailed communications from the Toronto team, the project reflects years of preparatory work aimed at translating promising laboratory findings into a rigorously designed clinical trial capable of meeting international regulatory standards.

Launched on 1 June 2026 and scheduled to run until May 2030, P-PEAKS UTI brings together a multidisciplinary consortium of clinicians, microbiologists, pharmacologists, regulatory specialists, and biotechnology partners across multiple continents. The Toronto coordination team has emphasized that one of the project’s primary goals is not only to demonstrate clinical efficacy but also to establish a reproducible framework for delivering personalized phage therapy at scale—something that has historically been a major barrier to broader adoption.

At its core, P-PEAKS UTI is a multicenter, intercontinental Phase II randomized controlled clinical trial designed to evaluate whether personalized bacteriophage therapy can safely and effectively prevent recurrent urinary tract infections caused by Escherichia coli. Unlike earlier phage therapy efforts, which were often limited to compassionate use cases or small observational studies, this trial is structured to generate high-quality, statistically robust evidence. The Toronto investigators have highlighted that this level of rigor is essential for gaining acceptance from regulatory agencies such as the European Medicines Agency and Health Canada.

The study plans to enroll 216 women suffering from recurrent urinary tract infections across nine specialized clinical sites located in North America, Europe, and the Middle East. These sites have been carefully selected based on their expertise in managing complex urinary infections and their capacity to implement advanced microbiological and clinical protocols. Importantly, the trial also includes renal transplant recipients, a particularly vulnerable population. In these patients, recurrent infections can lead to severe complications, including graft dysfunction, systemic infection, and increased hospitalization rates. By including such high-risk individuals, the study aims to assess both the safety and the broader applicability of phage therapy in real-world clinical scenarios.

One of the defining features of P-PEAKS UTI, as emphasized by the Toronto team, is its combination therapy approach. Rather than attempting to replace antibiotics entirely, the trial investigates how bacteriophages can be integrated with conventional antimicrobial treatments to enhance overall efficacy. Participants in the treatment arm will receive personalized bacteriophages through multiple routes of administration: orally during the first two days to target intestinal reservoirs of E. coli, intravesically via bladder instillation on the first day to directly reach the site of infection, and topically through the vaginal route over a five-day period to address potential reservoirs in the urogenital tract. This multi-route strategy reflects a comprehensive understanding of the ecological niches where uropathogenic bacteria can persist.

In addition to phage therapy, both the treatment and control groups will receive a single intravenous dose of a beta-lactam antibiotic on the second day. According to the Toronto investigators, this design allows researchers to isolate the added value of phage therapy while maintaining a baseline level of standard care. The combination is also intended to exploit potential synergistic effects between phages and antibiotics, particularly in disrupting biofilms and enhancing bacterial clearance.

The scientific rationale behind this approach is grounded in a growing body of experimental evidence. Bacteriophages have the unique ability to infect and replicate within bacterial cells, leading to targeted bacterial lysis. Importantly, certain phages produce enzymes known as depolymerases that can degrade components of the biofilm matrix, facilitating deeper penetration and increased susceptibility of bacteria to both phages and antibiotics. The Toronto team has highlighted that this dual mechanism—mechanical disruption of biofilms combined with targeted bacterial killing—could represent a major advantage over antibiotics alone.

Another major innovation of P-PEAKS UTI is its implementation of personalized phage therapy at an unprecedented scale. Each patient’s bacterial isolate will undergo detailed characterization and standardized susceptibility testing to identify the most effective phages. Artificial intelligence tools, developed in collaboration with computational biology teams, will assist in rapidly matching phages to bacterial targets. According to project leaders in Toronto, these AI-driven approaches are critical for reducing turnaround times and ensuring that patients receive timely, tailored treatments.

The project also integrates both GMP-manufactured phages and magistral preparations, reflecting the evolving regulatory landscape in Europe and beyond. This dual approach allows the consortium to explore different production and distribution models, with the ultimate goal of identifying scalable solutions that can be implemented in routine clinical practice.

Beyond its primary clinical endpoints, P-PEAKS UTI includes an extensive translational research program. Investigators will study the pharmacokinetics and pharmacodynamics of administered phages, tracking how they distribute within the body, how long they persist, and how they interact with bacterial populations. Immune responses to phage therapy will also be closely monitored, as the development of anti-phage antibodies could influence treatment efficacy. Additionally, comprehensive analyses of the urinary and intestinal microbiomes will be conducted to assess how phage therapy impacts microbial ecosystems over time.

The Toronto coordination team has also placed strong emphasis on regulatory science and health economics. Detailed cost-effectiveness analyses will compare personalized phage therapy with conventional antibiotic regimens, providing critical data for healthcare decision-makers. Close collaboration with regulatory authorities aims to establish standardized data packages that could support future marketing authorization. This aspect of the project is particularly important, as regulatory uncertainty has historically been a major obstacle to the widespread adoption of phage therapy.

Patient-centered research is another key component of the project. Surveys and qualitative studies will explore patient perceptions of phage therapy, including issues related to acceptability, convenience, and potential stigma. According to the Toronto investigators, understanding patient perspectives is essential for ensuring successful implementation, as even the most effective therapies must be acceptable to those who receive them.

Ultimately, P-PEAKS UTI seeks to determine whether precision bacteriophage therapy can become a viable, scalable, and clinically validated solution for preventing recurrent urinary tract infections. By reducing reliance on antibiotics and targeting the underlying mechanisms of persistence, such as biofilm formation, the project has the potential to significantly improve patient outcomes while contributing to global efforts to combat antimicrobial resistance.

As one of the largest and most comprehensive randomized clinical trials ever conducted in the field of bacteriophage therapy, P-PEAKS UTI represents a major milestone in the transition from experimental approaches to evidence-based infectious disease treatment. The detailed framework developed by the Unity Health Toronto team and its international partners could serve as a blueprint for future phage therapy trials across a wide range of bacterial infections. If successful, the project may help redefine how recurrent infections are managed, offering new hope to patients who currently face limited and often ineffective treatment options.



Source :

European Commission – CORDIS. P-PEAKS UTI (Grant Agreement No. 101289070). DOI: https://doi.org/10.3030/101289070

Toronto University : https://unityhealth.to/2026/06/international-trial-using-viruses-to-treat-drug-resistant-infections/

Comments

Post a Comment

Most Consulted Articles

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more

EMA : Guideline on quality aspects of phage therapy medicinal products

-
Image
The European Medicines Agency Publishes Draft Guideline on Quality Aspects of Phage Therapy Medicinal Products: A Landmark in the Regulation of Bacteriophage Therapeutics Introduction On 16 October 2025 , the European Medicines Agency (EMA) , through its Committee for Medicinal Products for Human Use (CHMP) and the Biologics Working Party (BWP) , adopted for public consultation the draft Guideline on Quality Aspects of Phage Therapy Medicinal Products (EMA/CHMP/BWP/1/2024) . This 15-page document represents the first comprehensive regulatory framework in the European Union specifically addressing the quality, manufacturing, and control requirements for bacteriophage-based medicinal products intended for human use. The release of this draft guideline is a significant milestone in the development of phage therapy as a legitimate, standardised, and potentially widely accessible treatment modality for bacterial infections, particularly in the context of the global antimicrobial resi...
Read more

EUCAST creates a Subcommittee on Phage susceptibility testing

-
Image
Subcommittee on Phage susceptibility testing Lytic bacteriophages, or phages, are viruses that infect and kill bacteria. Phage therapy is emerging as a promising adjuvant to traditional antimicrobials for combatting difficult-to-treat bacterial infections. However, implementation of phage-based treatments requires standardized methods for testing their efficacy to select the optimal therapeutic phages. To address this, EUCAST has established the EUCAST Phage Susceptibility Testing (PST) Subcommittee Remit of the PST Subcommittee : - Developing  standardized reference methods  to ensure uniform and reproducible  in vitro  phage susceptibility testing across laboratories worldwide, - Establishing  criteria for interpretation of PST results , providing clinicians and researchers with evidence-based guidelines to assess phage efficacy and monitor phage activity. - Promoting  quality assurance  by implementing stringent  quality control  measures ...
Read more